Format

Send to

Choose Destination
Arch Med Sci. 2011 Apr;7(2):189-94. doi: 10.5114/aoms.2011.22067. Epub 2011 May 17.

Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis.

Author information

1
Department of Rheumatology and Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland.

Abstract

Antibodies to citrullinated proteins/peptides (ACPAs) are the second serological marker to have recently been included in the 2010 ACR/EULAR Rheumatoid Arthritis (RA) Classification Criteria, which are focused on early diagnosis and therapy. This review discusses their history and some clinical aspects of ACPAs, focusing on the diagnostic utility of anti-cyclic citrullinated peptide (anti-CCP) antibodies as a marker of RA as compared to the widely used rheumatoid factor (RF). Simultaneously, this review aims to raise physician awareness and interest in anti-citrullinated vimentin antibody (anti-Sa/anti-MCV), another member of the ACPA family, which appears to have a better predictive value as a marker of RA than anti-CCP or RF and correlates closely with disease activity and therapeutic response among patients with RA.

KEYWORDS:

American College of Rheumatology; anti-Sa; anti-cyclic citrullinated peptide; anti-mutated citrullinated vimentin; antibodies to citrullinated protein/peptide; rheumatoid arthritis

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center